C-HCA - Key Persons

Henning Schade, MD is an Assistant Member Physician at the Colorado Blood Cancer Institute and part of the Plasma Cell and Lymphoid Disease Groups. Dr. Schade completed his Bone Marrow Transplant Fellowship Program at CBCI in 2017 and joined immediately afterward. Dr. Schade is board certified in Internal Medicine and Oncology and has focused his training in Bone Marrow Transplantation and Malignant Hematology. Dr. Schade was born and raised in Hesse, Germany. He stayed in his hometown near Frankfurt/Main until completion of high school when he decided to join a Catholic church group for a mandatory civilian service. Henning has been dedicated to patient care since he started working with patients and elderly with special needs during this period of civilian service. This inspired him to join nursing school for a 3-year training to become licensed nurse. Soon after he finished nursing school in 1998, he signed up for medical school training. He continued to work as a part-time nurse during this time. After finishing med school in 2006 he joined UK-S-H in Kiel, Germany to initiate training as an internal medicine resident and BMT trainee at the bone marrow transplantation center at MSH Kiel. He stayed there until 2010 when he decided to move to the US to continue training as a physician. Dr. Schade then finished a residency in internal medicine in 2014 at MUSC in Charleston South Carolina. He then joined University of Colorado/Anschutz for a Hematology/Oncology Fellowship. After completion in 2016, he joined Colorado Blood Cancer Institute for dedicated BMT fellowship year. Dr. Schade has published several scientific articles, abstracts and posters at ASCO, ASH and EBMT, including his doctoral thesis about second allogeneic stem cell transplantation in patients with relapsed hematologic malignancy. During his time as an internal medicine resident at MUSC he worked in Dr. Yubin Kang's lab on Multiple Myeloma cell lines and became interested in translational research. During his fellowship in Hematology/Oncology at the University of Colorado he worked in Brent Palmer's lab and studied PD-1 expression on CD4+ T cells and CMV+ T cells after allogenic stem cell transplantation. The results were published in BBMT in 08/2016. These findings were the fundamental basis for his upcoming research projects. Dr. Schade's research interest is primarily in the treatment of plasma cell and lymphoid diseases. He is the primary investigator for several clinical studies that investigate novel treatment options for patients with Multiple Myeloma and Hodgkin lymphoma. He also has a strong research interest in immune reconstitution after autologous and allogenic stem cell transplantation and has published his research in journals such as BBMT. At The Colorado Blood Cancer Institute he developed an investigator initiated a phase 1 protocol for patients with chemotherapy-refractory AML/MDS using GVHD prophylaxis with posttransplant cyclophosphamide followed by PD-1 inhibition with Nivolumab for consolidation. This protocol now offers a potentially curative treatment option for patients that otherwise would not meet criteria to undergo allogenic stem cell transplantation. Dr. Schade loves to bake all kinds of goodies including sourdough bread, bagels and New York style pizza. He also loves to go fishing with his kids. He loves the outdoors and can be found in the mountains hiking and skiing with his family. Dr. Schade is an enthusiastic fan of the Denver Nuggets and he of course is a big fan of European soccer. Education Medical School

Jeffrey Matous, MD, is a Member Physician at the Colorado Blood Cancer Institute and part of the Plasma Cell Diseases Group. Dr. Matous became a member of CBCI in 2010. He is presently a clinical professor of medicine at the University of Colorado Health Sciences Center. Dr. Matous is also on the board of the Leukemia-Lymphoma Society. Dr. Matous was born in Sarnia, Ontario, Canada but raised in Seattle, Washington. Dr. Matous received his medical degree with honors from the University of Washington. He completed his internal medicine residency and chief residency at the University of Colorado Health Sciences Center. His fellowship training in hematology and bone marrow transplantation was completed at the University of Washington and the Fred Hutchinson Cancer Research Center. He returned to Denver to practice at Rocky Mountain Cancer Centers in 1994, where he worked until 2010 before moving to CBCI. Dr. Matous specializes in the treatment of blood cancers such as multiple myeloma, Waldenstrom Macroglobulinemia and amyloidosis as well as in the field of blood & marrow transplantation. Dr. Matous has a particular interest in medical education and supervises both medical students and internal medicine residents who are interested in the field of hematology/oncology. Dr. Matous has been recognized as an outstanding clinical teacher of the medicine house staff. He is the lead investigator in clinical trials in the areas of Waldenstrom's Macroglobulinemia, multiple myeloma, and amyloidosis, and has been recognized by his peers as Top Doctor for the past 16 years. He is passionate about educating patients with these diseases. Dr. Matous is married with three adult children. Outside of work he enjoys cycling, languages, and our nation's pastime. Education Medical School University of Washington School of Medicine , specializes in the treatment of blood cancers such as multiple myeloma, lymphoma, chronic leukemia, waldenstrom macroglobulinemia and amyloidosis as well as in the field of blood & marrow transplantation. Dr. Matous is married, has three children and enjoys language, cycling and is an avid Rockies fan. To learn more about Dr. Matous, visit www.bloodcancerinstitute.com Dr. Jeffrey Matous, M.D. details what is important to know when you have a blood cancer and how to educate yourself on treatment options and clinical trials...

Job Titles:

• Assistant

Luke Mountjoy is an Assistant Member Physician at the Colorado Blood Cancer Institute and part of the Lymphoid Disease Group. Dr. Mountjoy joined CBCI in 2020. He is board certified in internal medicine and medical oncology/hematology. Dr. Mountjoy earned his Bachelor of Science in Biology from the University of Colorado at Denver during which time he worked as an EMT in the Denver area. Dr. Mountjoy was born and raised in Denver, Colorado. His interest in medicine began as a teenager when is father was diagnosed with pancreatic cancer. Shortly after his father's diagnosis, Dr. Mountjoy was diagnosed with acute leukemia. These life experiences led him to pursue a career in medicine with plans to become a medical oncologist/hematologist. He graduated from Des Moines University and did his residency in internal medicine at the University of Iowa where he also served as chief resident. Dr. Mountjoy then moved to Phoenix, Arizona to complete subspecialty training in medical oncology/hematology at the Mayo Clinic. During training, Dr. Mountjoy spent much of his research time in stem cell transplant and prevention/management of graft-versus-host disease. He also worked closely with the laboratory team to identify novel strategies of testing for drug resistances in patients undergoing treatment for multiple myeloma. Finally, he was part of a large research team that is actively working to identify genetic risk factors/predispositions in patients and families with newly diagnosed cancers. Dr. Mountjoy has passion for hematologic malignancies with emphasis on lymphoma, leukemia, and stem cell transplant. He is an active member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. Mountjoy enjoys snowboarding, hiking, tennis, and spending time with his family. Education Medical School Des Moines University

Marcello Rotta, MD is an Assistant Member Physician at the Colorado Blood Cancer Institute. He Joined CBCI in 2016. Here he serves as Co-Director of the Leukemia Service, and on the Long Term Follow up Service. He is Board Certified in Internal Medicine. Hematology and Medical Oncology. Dr Rotta is an avid hiker and biker and enjoys the Colorado outdoors with his wife and their three children. Dr Rotta has a personal involvement and a life commitment to high quality care for patient with leukemia and others hematological malignancies.

Job Titles:

• Specializes in the Treatment of Patients With Blood Cancers As Well As Expertise in the Use of Blood and Marrow Transplantation for.

Michael Maris, MD, is a Member Physician and Director of Research at the Colorado Blood Cancer Institute and part of the Myeloid and Lymphoid Disease Groups. Dr. Maris has been a member of CBCI since 2003. Dr. Maris specializes in the treatment of patients with blood cancers and holds strong expertise in the use of blood and marrow transplantation for hematologic malignancies. Dr. Maris is board certified in medical oncology. Dr. Maris was born in Eastern Ohio and raised both in Central New Jersey and North of Pittsburgh. He received his undergraduate degree at West Virginia University. He worked in the laboratory of Dr. Britton Chance at the University of Pennsylvania developing noninvasive near-infrared modalities to assess tissue oxygenation and physiologic and disease states. Dr. Maris received his medical degree from the University of Pennsylvania. He completed his internal medicine residency at the Oregon Health Sciences University in Portland, Oregon. Dr. Maris completed his oncology and blood and marrow transplantation fellowship at the Fred Hutchinson Cancer Research Center/University of Washington in Seattle, Washington. Dr. Maris' research focus at that time was expanding the role of allogeneic transplantation to older and infirm patients through the use of non-myeloablative allogeneic hematopoietic stem cell transplantation. Dr. Maris has published extensively in this area. Dr. Maris' current research interests are in further optimizing allogeneic hematopoietic transplantation for patients of all types as well as the development of novel drug and drug regimens for the treatment of the patients with acute myeloid leukemia. Dr. Maris has extensive experience as an investigator in multiple clinical trials and Dr. Maris has expertise in the treatment of patients with acute myeloid leukemia. He believes that physicians are educators/guides during the cancer treatment process and patients should be empowered with the knowledge to guide their decisions. Patient understanding of the underlying disease process and therapeutic options is a requirement in the shared clinical decision making between the patient and his/her physician. Dr. Maris enjoys spending time with his family. In his free time he enjoys hiking, skiing, running, biking, and travel. Education Medical School University of Pennsylvania School of Medicine Michael B. Maris, MD specializes in the treatment of patients with blood cancers as well as expertise in the use of blood and marrow transplantation for hematologic malignancies. Dr. Maris is the Research Director for the Colorado Blood Cancer Institute and Rocky Mountain Blood and Marrow Transplant Program. Dr. Maris' current research interests are in further optimizing allogeneic hematopoietic transplantation for patients of all types as well as the development of novel drug and drug regimens for the treatment of the patients with acute myeloid leukemia. To learn more, visit www.bloodcancerinstitute.com Dr. Michael Maris, M.D. explains how research studies are used to determine if a drug is safe, effective and potential better than the standard of care... Dr. Michael Maris, M.D. details how the treatment of lymphomas has changed dramatically over the past decade. To learn more, call us at 720-754-4800

Job Titles:

• Associate

Michael Tees, MD, is an Associate Member Physician at the Colorado Blood Cancer Institute and part of the Lymphoid and Autoimmune Disease Groups. Dr. Tees joined CBCI in 2015 and is board certified in Hematology, Medical Oncology, and Internal Medicine. Dr. Tees was born in upstate New York and grew up in Jacksonville, Florida. After high school he attended the University of Florida, receiving an undergraduate degree in Microbiology and Cell Science as well as Business Administration. Dr. Tees completed medical training at Tulane University School of Medicine in New Orleans. He simultaneously received a Master of Public Health in Epidemiology from the Tulane University School of Public Health and Tropical Medicine. He did his residency in internal medicine at New York University. During his hematology and medical oncology fellowship at the Moffitt Cancer Center and Research Institute in Tampa, Florida, he specialized in hematopoietic stem cell transplantation and cellular therapy. Dr. Tees has a strong interest in the treatment and management of lymphocytic diseases. His current research focuses on novel cellular and immune-based therapies in those with lymphomas and other lymphocytic disorders. He currently is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society of Transplantation and Cellular Therapy. In addition, he is a member of the Sarah Cannon Lymphoma Working Group. In his spare time, Dr. Tees advocates for patients by serving on the board of directors for the Rocky Mountain Chapter of the Leukemia and Lymphoma Society. He enjoys skiing and hiking, and he never misses an opportunity to be outdoors. When traveling, he loves to SCUBA dive and visit exciting new places off the beaten path. Education Medical School Tulane University Michael Tees M.D., MPH, primary field on interest is on the treatment and management of lymphoid diseases. His research interests have focused on post-...

Richard Nash, MD, is a Member Physician at the Colorado Blood Cancer Institute and part of the Autoimmune and Supportive Care Disease Groups. Dr. Nash joined the Rocky Mountain Blood and Marrow Transplant Program in 2011. Dr. Nash is board certified in internal medicine, hematology and oncology. Dr. Nash is originally from Canada. He obtained his medical degree from the University of Manitoba and completed his clinical training in internal medicine, hematology and oncology at the Manitoba-Affiliated Teaching Hospitals in Winnipeg. He completed a research fellowship in transplantation biology at the Fred Hutchinson Cancer Research Center in Seattle, Washington. Before coming to Denver, Colorado he was on faculty for 21 years and became a full member of the Fred Hutchinson Cancer Research Center. He was also a professor of medicine at the University of Washington. As well as specializing in the treatment of hematological malignancies and other non-malignant blood disorders, he is an expert in the field of blood and marrow transplantation with an interest in managing patients with complications of transplantation including GVHD. He also has a national reputation for his work investigating the use of blood and marrow transplantation for treatment of severe autoimmune diseases like systemic sclerosis and multiple sclerosis. Dr. Nash has served on numerous national committees and conducted extensive research on autoimmune diseases and the complications of blood and marrow transplantation. He is the author or co-author of more than 200 articles and book chapters in the medical literature. He enjoys working with patients and getting to know them and their families. Patients are faced with many difficult decisions, so Dr. Nash tries to guide them in assessing their treatment options. In his free time, Dr. Nash enjoys riding his bike and is working on riding across the nation, doing a portion of the trip each year. Education Medical School University of Manitoba As well as specializing in the treatment of hematological malignancies and other non-malignant blood disorders, Richard Nash, MD, is an expert in the field...

Job Titles:

• Research Institute Michael Maris, M.D. Colorado Blood Cancer Institute

Scott Bearman, MD, is a Member Physician at the Colorado Blood Cancer Institute and works on the inpatient team. Dr. Bearman joined the Rocky Mountain Blood and Marrow Transplant Program in 2003. Dr. Bearman is board certified in internal medicine and oncology/hematology. Dr. Bearman earned his undergraduate degree at Tufts University. Dr. Bearman grew up in Miami, Florida. He graduated from Tufts University School of Medicine in Boston, Massachusetts and did a residency in internal medicine at The University of Washington and the Fred Hutchinson Cancer Research Center in Seattle, Washington. After serving as an associate in clinical research at the Fred Hutchinson Cancer Research Center, Dr. Bearman became clinical director of the bone marrow transplant program at the University of Colorado Health Sciences Center in 1991. He also served as the director of the allogeneic bone marrow transplantation at UCHSC. Dr. Bearman was the director of clinical investigations core at the University of Colorado Cancer Center. Dr. Bearman is a member of several societies, including the American Foundation for Medical Research, the American Society of Hematology, the American Society of Clinical Oncology, the American College of Physicians and the American Society for Blood and Marrow Transplantation. Dr. Bearman has served on numerous national committees, conducted extensive research and is the author or co-author of more than 100 articles and book chapters in medical literature. Dr. Bearman and his wife Terri have a son and a daughter, both of whom are grown, and a dog who is older than he is in dog years. Together they enjoy travel and greatly appreciate good food. In his free time Dr. Bearman golfs (he describes his game as ‘embarrassing') and plays guitar. Education Medical School Tufts University School of Medicine Scott Bearman, MD, is board certified in internal medicine and oncology/hematology, and earned his undergraduate degree at Tufts University. Dr. Bearman has served on numerous national committees, conducted extensive research and is the author or co-author of more than 100 articles and book chapters in medical literature. Dr. Bearman is a member of several societies, including the American Foundation for Medical Research, the American Society of Hematology, the American Society of Clinical Oncology, the American College of Physicians and the American Society for Blood and Marrow Transplantation. To learn more about Dr. Bearman, visit www.bloodcancerinstitute.com Dr. Scott Bearman, M.D. explains that bone marrow and steam cell transplants are essentially the same thing and the different transplants used for different...

Job Titles:

• Co - Director of the Plasma Cell Dyscrasia Program at CBCI

Tara Gregory, MD, is a Member Physician at the Colorado Blood Cancer Institute and part of the Plasma Cell Disease Group. Dr. Gregory joined CBCI in 2009 and is board certified in internal medicine and medical oncology. Dr. Gregory earned her Bachelor of Arts summa cum laude in Hispanic Linguistics and her honors thesis focused on the critical age of learning and brain plasticity. She is fluent in Spanish. She also received her Bachelor of Science in molecular and cellular biology summa cum laude and wrote her honors thesis on the expression of iNOS in mouse cardiac transplant grafts. Dr. Gregory was born and raised in Scottsdale, Arizona. Her father was a physician, giving her an early exposure to a career in healthcare. She graduated from the University of Arizona School of Medicine in Tucson, Arizona and did a residency in internal medicine at the Banner Good Samaritan/Carl T. Hayden VAMC program. Dr. Gregory then moved to Denver, Colorado to complete her medical oncology fellowship at the University of Colorado. After finishing fellowship, Dr. Gregory was the first blood and marrow transplant fellow at CBCI and has since joined the program as a BMT physician. She has been recognized by the house staff for excellence and dedication to teaching. Dr. Gregory is the co-director of the Plasma Cell Dyscrasia Program at CBCI focusing on diseases such as multiple myeloma, amyloidosis, monoclonal gammopathies and plasma cell leukemia. The focus of her research work is in multiple myeloma treatments including chimeric antigen T cell therapy. She is a member of the International Myeloma Society. In addition to her research publications and presentations at national meetings, Dr. Gregory has been accepted to the American Society of Transplant and Cellular Therapies National Leadership Program. Dr. Gregory is passionate about educating patients to ensure they understand their disease and working in partnership with patients to make treatment decisions that honor quality of life as well as outcomes. Dr. Gregory is a member of several societies, including the American Society of Hematology, the American Society of Clinical Oncology and the American Society for Blood and Marrow Transplantation. Dr. Gregory participates in clinical trials including research in blood and marrow transplant outcomes, the results which have been presented at multiple research meetings. Dr. Gregory lives in Denver with her wonderful family and dogs and enjoys exercising at Orangetheory Fitness as well as recreating at her Salida home with hiking, skiing and family time. Education Medical School University of Arizona College of Medicine Dr. Tara Gregory, M.D. explains how multiple myeloma is identified in the body, the effects it can have, and when treatment is necessary. To learn more... Dr. Tara Gregory, M.D. shares how they are using tests and drugs to manage and treat patients of myeloma by determining how much myeloma is in the body... Dr. Tara Gregory, M.D. explains how a patient can learn more about clinical trials that are available and how to participate. To learn more, visit our ... Tara Gregory, MD, joined the Colorado Blood Cancer Institute in 2009. She is from Scottsdale, Arizona and attended the University of Arizona and completed...

Dr. Jeffrey Matous, M.D. discusses Waldenström Macroglobulinemia, (WM) a rare type of non-Hodgkin lymphoma and the treatment options through clinical trials...